{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:50:40Z","timestamp":1781945440162,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.thromres.2025.109580","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:57:43Z","timestamp":1767718663000},"page":"109580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Improvements in pharmacokinetics, bleeding control, and cost analysis after PK-guided transition to extended-half-life factor IX in hemophilia B: A multicentric study"],"prefix":"10.1016","volume":"258","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3169-5253","authenticated-orcid":false,"given":"Maria","family":"Chovi-Trull","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-5341","authenticated-orcid":false,"given":"Juan Eduardo","family":"Meg\u00edas-Vericat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1632-9674","authenticated-orcid":false,"given":"Tom\u00e1s","family":"Palanques-Pastor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-9924","authenticated-orcid":false,"given":"Ana Cid","family":"Haro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Rodriguez","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Palomero","family":"Massanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shally Marcellini","family":"Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9295-4714","authenticated-orcid":false,"given":"Saturnino Haya","family":"Guaita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Garc\u00eda","family":"Pellicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1800-6198","authenticated-orcid":false,"given":"Jose Luis Poveda","family":"Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-8211","authenticated-orcid":false,"given":"Santiago Bonanad","family":"Boix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 6(S6)","key":"10.1016\/j.thromres.2025.109580_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"12","key":"10.1016\/j.thromres.2025.109580_bb0010","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jth.13867","article-title":"Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH","volume":"15","author":"Iorio","year":"2017","journal-title":"J. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2025.109580_bb0015","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/jth.14153","article-title":"Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH","volume":"16","author":"Ragni","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109580_bb0020","series-title":"Therapeutic Advances in Hematology","article-title":"Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities\u2014a practical review","volume":"vol. 11","author":"Hermans","year":"2020"},{"issue":"3","key":"10.1016\/j.thromres.2025.109580_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102397","article-title":"Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B","volume":"8","author":"Goedhart","year":"2024","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2025.109580_bb0030","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/17474086.2018.1489719","article-title":"The benefits of prophylaxis in patients with hemophilia B","volume":"11","author":"Castaman","year":"2018","journal-title":"Expert Rev. Hematol."},{"issue":"10","key":"10.1016\/j.thromres.2025.109580_bb0035","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1080\/13696998.2019.1620246","article-title":"Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP","volume":"22","author":"Davis","year":"2019","journal-title":"J. Med. Econ."},{"issue":"4","key":"10.1016\/j.thromres.2025.109580_bb0040","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/hae.14307","article-title":"Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: longitudinal follow-up in a national adult cohort","volume":"27","author":"O\u2019Donovan","year":"2021","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.thromres.2025.109580_bb0045","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/hae.13432","article-title":"Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B","volume":"24","author":"Wang","year":"2018","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.thromres.2025.109580_bb0050","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/jth.14778","article-title":"Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults\/adolescents with hemophilia B","volume":"18","author":"Mancuso","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2025.109580_bb0055","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/hae.14369","article-title":"Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: a Canadian observational study of real-world outcomes","volume":"27","author":"Sun","year":"2021","journal-title":"Haemophilia"},{"issue":"9","key":"10.1016\/j.thromres.2025.109580_bb0060","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1007\/s12325-023-02559-1","article-title":"Real-world effectiveness of rFIXFc prophylaxis in patients with Haemophilia B switched from standard half-life therapy in three European countries","volume":"40","author":"Funding E","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.thromres.2025.109580_bb0065","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241311535","article-title":"Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France","volume":"16","author":"Chambost","year":"2025","journal-title":"Ther. Adv. Hematol."},{"issue":"3","key":"10.1016\/j.thromres.2025.109580_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12661","article-title":"Switching to nonacog beta pegol in hemophilia B: outcomes from a Canadian real-world, multicenter, retrospective study","volume":"6","author":"Matino","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2025.109580_bb0075","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1007\/s12325-020-01300-6","article-title":"Real-world utilisation and bleed rates in patients with haemophilia B who switched to recombinant factor IX fusion protein (rIX-FP): a retrospective international analysis","volume":"37","author":"Hermans","year":"2020","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.thromres.2025.109580_bb0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/hae.14689","article-title":"IDEAL study: a real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy","volume":"29","author":"Tagliaferri","year":"2023","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.thromres.2025.109580_bb0085","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/hae.13970","article-title":"The Australian experience with switching to extended half-life factor VIII and IX concentrates: on behalf of the Australian Haemophilia Centre directors\u2019 organisation","volume":"26","author":"Brennan","year":"2020","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.thromres.2025.109580_bb0090","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1111\/hae.12995","article-title":"Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product","volume":"22","author":"Chowdary","year":"2016","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.thromres.2025.109580_bb0095","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/hae.13624","article-title":"Health-related quality of life in paediatric haemophilia B patients treated with rIX-FP","volume":"25","author":"von Mackensen","year":"2019","journal-title":"Haemophilia"},{"issue":"24","key":"10.1016\/j.thromres.2025.109580_bb0100","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.thromres.2025.109580_bb0105","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.thromres.2025.109580_bb0110","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.thromres.2025.109580_bb0115","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1111\/jth.12912","article-title":"Longer-acting clotting factor concentrates for hemophilia","volume":"13","author":"Powell","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.thromres.2025.109580_bb0120","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40265-023-01868-7","article-title":"Eftrenonacog alfa: a review in haemophilia B","volume":"83","author":"Lamb","year":"2023","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.thromres.2025.109580_bb0125","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1182\/blood-2011-02-335596","article-title":"Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B","volume":"118","author":"Negrier","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2025.109580_bb0130","doi-asserted-by":"crossref","first-page":"E694","DOI":"10.1097\/HS9.0000000000000694","article-title":"Predicting individual changes in terminal half-life after switching to extended half-life concentrates in patients with severe hemophilia","volume":"6","author":"Versloot","year":"2022","journal-title":"Hemasphere"},{"issue":"10","key":"10.1016\/j.thromres.2025.109580_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-234142","article-title":"Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain","volume":"13","author":"Rodr\u00edguez L\u00f3pez","year":"2020","journal-title":"BMJ Case Rep."},{"issue":"7","key":"10.1016\/j.thromres.2025.109580_bb0140","first-page":"643","article-title":"Real-world analysis of dispensed IUs of coagulation factor IX and resultant expenditures in hemophilia B patients receiving standard half-life versus extended half-life products and those switching from standard half-life to extended half-life products","volume":"24","author":"Tortella","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.thromres.2025.109580_bb0145","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2147\/JBM.S418818","article-title":"Real-world amount of clotting factor concentrates dispensed and annual medical expenditures for Japanese patients with hemophilia B","volume":"14","author":"Fukutake","year":"2023","journal-title":"J. Blood Med."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825003305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825003305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:17:49Z","timestamp":1781943469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825003305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":29,"alternative-id":["S0049384825003305"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109580","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvements in pharmacokinetics, bleeding control, and cost analysis after PK-guided transition to extended-half-life factor IX in hemophilia B: A multicentric study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109580"}}